Concepedia

Andreas Hagen Røssevold

AH

Statistics

Publications

7

Citations

375

H-Index

7

Active since

2019

Affiliations

Oslo University Hospital(Current)

University of Oslo

OsloMet – Oslo Metropolitan University

Stavanger University Hospital

St Olav's University Hospital

Andreas Hagen Røssevold is an author at Oslo University Hospital specializing in oncology, medicine, and pd-l1 blockade.

Publications per year

2019–2024

7

Publications

7

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment

Xavier Tekpli, Tonje G. Lien, Andreas Hagen Røssevold et al. · Nature Communications · 2019 · 209 citations · Full text

Medicine, Immunology, Oncology +17

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Bjerre et al. · Nature Medicine · 2022 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

Jon Amund Kyte, Andreas Hagen Røssevold, Ragnhild Sørum Falk et al. · Journal of Translational Medicine · 2020 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

Gut microbiota diversity is prognostic and associated with benefit from chemo‐immunotherapy in metastatic triple‐negative breast cancer

Andreas Ullern, Kristian Holm, Andreas Hagen Røssevold et al. · Molecular Oncology · 2024 · 18 citations · Full text

Life Sciences, Microbiology, Oncology +17

Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Nikolai Kragøe Andresen, Andreas Hagen Røssevold, Claire Quaghebeur et al. · Journal for ImmunoTherapy of Cancer · 2024 · 16 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 7